[go: up one dir, main page]

WO1997047290B1 - Systemes liquisolides et leurs procedes de production - Google Patents

Systemes liquisolides et leurs procedes de production

Info

Publication number
WO1997047290B1
WO1997047290B1 PCT/US1997/010093 US9710093W WO9747290B1 WO 1997047290 B1 WO1997047290 B1 WO 1997047290B1 US 9710093 W US9710093 W US 9710093W WO 9747290 B1 WO9747290 B1 WO 9747290B1
Authority
WO
WIPO (PCT)
Prior art keywords
liquid
powder
carrier
coating
liquisolid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1997/010093
Other languages
English (en)
Other versions
WO1997047290A1 (fr
Filing date
Publication date
Priority claimed from US08/658,514 external-priority patent/US5800834A/en
Priority to CA002257890A priority Critical patent/CA2257890C/fr
Priority to JP10501792A priority patent/JP2000512295A/ja
Priority to HK00101977.5A priority patent/HK1022844B/en
Priority to DE69740040T priority patent/DE69740040D1/de
Priority to BR9709778-0A priority patent/BR9709778A/pt
Application filed filed Critical
Priority to AT97929921T priority patent/ATE486584T1/de
Priority to IL12729596A priority patent/IL127295A/en
Priority to AU33870/97A priority patent/AU709566C/en
Priority to EP97929921A priority patent/EP0946154B1/fr
Publication of WO1997047290A1 publication Critical patent/WO1997047290A1/fr
Publication of WO1997047290B1 publication Critical patent/WO1997047290B1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Abstract

Les systèmes liquisolides consistent en des formes pulvérulentes d'une fluidité et d'une compressibilité acceptables de médicaments liquides. Selon le concept des systèmes liquisolides, des médicaments lipophiles liquides ou des médicaments hydro-insolubles, dissous dans des solvants non volatils appropriés, peuvent être convertis en poudres coulantes et facilement compressibles, par simple mélange avec des excipients en poudre sélectionnés appelés matières de support et matières d'enrobage. On peut faire un croquis schématique des différentes étapes du procédé. Plusieurs catégories de cellulose microcristalline ou amorphe peuvent être utilisées comme matière de support, tandis que des poudres de silice à particules très fines peuvent être utilisées comme matière d'enrobage. En se fondant sur la théorie selon laquelle les matières de support et d'enrobage ne peuvent retenir qu'une certaine quantité de liquide tout en conservant en même temps une compressibilité et une fluidité acceptables, on a mis au point un nouveau modèle mathématique de formulation permettant de calculer les quantités maximales de matières de support et d'enrobage nécessaires pour produire des mélanges liquide/poudre d'une fluidité et d'une compressibilité acceptables.
PCT/US1997/010093 1996-06-10 1997-06-09 Systemes liquisolides et leurs procedes de production Ceased WO1997047290A1 (fr)

Priority Applications (9)

Application Number Priority Date Filing Date Title
EP97929921A EP0946154B1 (fr) 1996-06-10 1997-06-09 Systemes liquisolides et leurs procedes de production
IL12729596A IL127295A (en) 1996-06-10 1997-06-09 Liquisolid systems and methods of preparing same
HK00101977.5A HK1022844B (en) 1996-06-10 1997-06-09 Liquisolid systems and methods of preparing same
DE69740040T DE69740040D1 (de) 1996-06-10 1997-06-09 Flüssigfeste systeme und verfahren zu deren herstellung
BR9709778-0A BR9709778A (pt) 1996-06-10 1997-06-09 Sistemas liquissólidos e métodos de preparação dos mesmos.
CA002257890A CA2257890C (fr) 1996-06-10 1997-06-09 Systemes liquisolides et leurs procedes de production
AT97929921T ATE486584T1 (de) 1996-06-10 1997-06-09 Flüssigfeste systeme und verfahren zu deren herstellung
JP10501792A JP2000512295A (ja) 1996-06-10 1997-06-09 リキソリッドシステムおよびそれを製造する方法
AU33870/97A AU709566C (en) 1996-06-10 1997-06-09 Liquisolid systems and methods of preparing same

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/658,514 US5800834A (en) 1996-06-10 1996-06-10 Liquisolid systems and methods of preparing same
US08/658,514 1996-06-10

Publications (2)

Publication Number Publication Date
WO1997047290A1 WO1997047290A1 (fr) 1997-12-18
WO1997047290B1 true WO1997047290B1 (fr) 1998-01-29

Family

ID=24641555

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1997/010093 Ceased WO1997047290A1 (fr) 1996-06-10 1997-06-09 Systemes liquisolides et leurs procedes de production

Country Status (12)

Country Link
US (2) US5800834A (fr)
EP (1) EP0946154B1 (fr)
JP (1) JP2000512295A (fr)
CN (1) CN1224379C (fr)
AT (1) ATE486584T1 (fr)
BR (1) BR9709778A (fr)
CA (1) CA2257890C (fr)
DE (1) DE69740040D1 (fr)
ES (1) ES2355871T3 (fr)
IL (1) IL127295A (fr)
RU (1) RU2209623C2 (fr)
WO (1) WO1997047290A1 (fr)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2159419C (fr) * 1994-10-17 2006-07-04 Pieter De Haan Composition pharmaceutique solide renfermant un excipient pouvant fixer l'eau
US6280770B1 (en) 1998-08-13 2001-08-28 Cima Labs Inc. Microemulsions as solid dosage forms for oral administration
US6635281B2 (en) 1998-12-23 2003-10-21 Alza Corporation Gastric retaining oral liquid dosage form
US6342249B1 (en) 1998-12-23 2002-01-29 Alza Corporation Controlled release liquid active agent formulation dosage forms
WO2000038655A1 (fr) * 1998-12-23 2000-07-06 Alza Corporation Formes posologiques comprenant des particules poreuses
US6793934B1 (en) 1999-12-08 2004-09-21 Shire Laboratories, Inc. Solid oral dosage form
US7029700B2 (en) * 2000-01-14 2006-04-18 Brown University Research Foundation Micronized freeze-dried particles
US7833549B2 (en) * 2000-01-19 2010-11-16 Mannkind Corporation Dry powder formulations of antihistamine for nasal administration
US6399101B1 (en) 2000-03-30 2002-06-04 Mova Pharmaceutical Corp. Stable thyroid hormone preparations and method of making same
US7056951B2 (en) 2000-09-26 2006-06-06 Mutual Pharmaceutical Co., Inc. Stable solid dosage forms of amino acids and processes for producing same
US6979462B1 (en) * 2000-10-03 2005-12-27 Mutual Pharmaceutical Co., Inc. Stabilization of solid drug formulations
US6855333B1 (en) 2000-10-03 2005-02-15 Mutual Pharmaceutical Co., Inc. Stabilization of solid thyroid drug formulations
US6692771B2 (en) 2001-02-23 2004-02-17 Cima Labs Inc. Emulsions as solid dosage forms for oral administration
AU2001241730B2 (en) * 2001-02-23 2007-03-15 Cima Labs Inc. Emulsions as solid dosage forms for oral administration
ITMI20012366A1 (it) * 2001-11-09 2003-05-09 Farmatron Ltd Sistemi terapeutici stabilizzati a rilascio immediato e/o modificato per la somministrazione orale di principi attivi e/o eccipienti e/o ali
US20030099699A1 (en) * 2001-11-13 2003-05-29 Hanshew Dwight D. Storage stable thyroxine active drug formulations and methods for their production
US6645526B2 (en) * 2001-11-13 2003-11-11 Mylan Pharmaceuticals, Inc. Storage stable thyroxine active drug formulations and methods for their production
KR20120066688A (ko) * 2003-02-24 2012-06-22 파마슈티칼 프로덕션스, 인크. 경점막 약물 전달 시스템
CA2540771A1 (fr) * 2003-09-30 2005-04-14 Spherics, Inc. Agents therapeutiques nanoparticulaires biologiquement actifs
MXPA06010146A (es) * 2004-03-08 2007-05-11 Spiridon Spireas Formas de dosificacion solidas biodisponibles de metaxalona.
MY142989A (en) 2004-03-10 2011-02-14 Bayer Schering Pharma Ag Stabilised supersaturated solids of lipophilic drugs
US20060057206A1 (en) * 2004-08-19 2006-03-16 Wong Patrick S Controlled release nanoparticle active agent formulation dosage forms and methods
FR2894822B1 (fr) * 2005-12-20 2011-11-18 Pf Medicament Composition pharmaceutique contenant des acides gras omega-3
US7569612B1 (en) 2006-08-21 2009-08-04 Mutual Pharmaceutical Company, Inc. Methods of use of fenofibric acid
EP2608773A4 (fr) * 2010-08-24 2014-03-05 Univ Rutgers Formulation et fabrication de produits pharmaceutiques par imprégnation sur supports poreux
CN102949363A (zh) * 2012-11-28 2013-03-06 山东省中医药研究院 熊果酸液固压缩片
US10660856B2 (en) 2013-02-01 2020-05-26 W. R. Grace & Co.-Conn. Porous silica gel as a carrier for liquid technologies
GB201812022D0 (en) * 2018-07-24 2018-09-05 Univ Of Sussex Pharmaceutical methods and compositions
US10744137B1 (en) * 2020-01-06 2020-08-18 King Abdulaziz University Liquisolid tablet containing combined dose of tadalafil and dapoxetine
CN111067875B (zh) * 2020-01-16 2021-11-30 兰州大学 一种阿苯达唑液固压缩片及其制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1368112A (en) * 1971-09-08 1974-09-25 Geistlich Soehne Ag Chemical compositions for the treatment of hyperlipemia
DE2400819C2 (de) * 1974-01-09 1982-04-22 Bayer Ag, 5090 Leverkusen Verfahren zur Herstellung fester Zubereitungen von schwerlöslichen Arzneimittelwirkstoffen in feinster Verteilung
SE8601624D0 (sv) * 1986-04-11 1986-04-11 Haessle Ab New pharmaceutical preparations
DE69222006T2 (de) * 1991-10-30 1998-01-22 Glaxo Group Ltd Mehrschichtzusammensetzungen enthaltend Histamin- oder Serotonin- Antagonisten

Similar Documents

Publication Publication Date Title
WO1997047290B1 (fr) Systemes liquisolides et leurs procedes de production
RU2209623C2 (ru) Способ получения свободно-текучей и легко прессуемой смеси жидкость-порошок (варианты), свободно-текучая и легко прессуемая смесь жидкость-порошок (варианты)
JP4672981B2 (ja) 錠剤化のための高圧縮性エチルセルロース
Bos et al. Native starch in tablet formulations: properties on compaction
RU99100314A (ru) Пластифицированные системы и способы их получения
Di Martino et al. Improved compression properties of propyphenazone spherical crystals
JPH0645564B2 (ja) 直接圧縮加工用粒状マンニトールおよびその製造方法
Wikberg et al. Compression characteristics of granulated materials II. Evaluation of granule fragmentation during compression by tablet permeability and porosity measurements
JP4371394B2 (ja) 制御された放出性ポリアクリル酸顆粒およびその製法
Ringard et al. Calculation of disintecrant critical concentration in order to optimize tablets disintegration
Nyström et al. Studies on direct compression of tablets. XIII. The effect of some dry binders on the tablet strength of compounds with different fragmentation propensity
Jerwanska et al. The effect of water content on the porosity and liquid saturation of extruded cylinders
RU2207133C2 (ru) Стабилизированные композиции тиболона
DE2426812A1 (de) Verfahren zur herstellung von granulaten
US3836618A (en) Process for the uniform distribution of a drug on a granulated base
WO1984000760A1 (fr) Granules de cellulose et leur procede de production
Gordonx et al. Manipulation of naproxen particle morphology via the spherical crystallization technique to achieve a directly compressible raw material
JPH0442441B2 (fr)
RU2001123429A (ru) Способ изготовления таблеток ядерного топлива из смешанного оксида (u, pu)o2 из нетекучего порошка uo2
Olsson et al. Evaluation of the effect of addition of polyethylene glycols of differing molecular weights on the mechanical strength of sodium chloride and sodium bicarbonate tablets
Mallick et al. Study of particle rearrangement, compression behavior and dissolution properties after melt dispersion of ibuprofen, Avicel and Aerosil
CN113057999B (zh) 一种树脂类蒙药粉配方颗粒及其制备方法
US20230372247A1 (en) Self-disintegrating excipient composition for solid oral dosage forms
Alderborn et al. Compression characteristics of granulated materials. I. Fragmentation propensity and compactibility of some granulations of a high dosage drug
Nilsson et al. Physicochemical aspects of drug release. V. The importance of surface coverage and compaction on drug dissolution from ordered mixtures